Announcement

Collapse
No announcement yet.

Who wrote the 2,000 page Affordable Care Act?

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Who wrote the 2,000 page Affordable Care Act?

    ​who do you think . . .

    “Insurers and the government have developed a symbiotic relationship, nurtured by tens of billions of dollars that flow from the federal Treasury to insurers each year.” Michael F. Cannon, director of health policy studies at the libertarian Cato Institute.

    Since the Affordable Care Act was enacted in 2010, the relationship between the Obama administration and insurers has evolved into a powerful, mutually beneficial partnership that has been a boon to the nation’s largest private health plans and led to a profitable surge in their Medicaid enrollment.

    Since Mr. Obama signed the law, share prices for four of the major insurance companies — Aetna, Cigna, Humana and UnitedHealth — have more than doubled, while the Standard & Poor’s 500-stock index has increased about 70 percent.

    “These companies all look at government programs as growth markets,” said Michael J. Tuffin, a former executive vice president of America’s Health Insurance Plans, the main lobby for the industry. “There will be nearly $2 trillion of subsidized coverage through insurance exchanges and Medicaidover the next 10 years. These are pragmatic companies. They will follow the customer.”

    The relationship is expected only to deepen as the two sides grow more intertwined.


    Federal law requires most Americans to have coverage, insurers provide it, and the government subsidizes it.

    “We are in this together,” Kevin J. Counihan, the chief executive of the federal insurance marketplace, told insurers at a recent conference in Washington. “You have been our partners,” and for that, he said, “we are very grateful.”

    WellPoint announced recently that it had gained 751,000 subscribers through the health insurance exchanges and 699,000 new members through Medicaid. Since the end of 2013, WellPoint’s Medicaid enrollment has increased by 16 percent, to a total of five million.


    “Our government business is growing along multiple fronts” and accounted for about 45 percent of the company’s consolidated operating revenues, said Joseph R. Swedish, the chief executive of WellPoint.

    Aetna, in reporting its third-quarter results, said many people thought 2014 would “spell the death of our industry.” But, the company said, it is having “a very good year,” thanks in part to “excellent performance in our government business, which now represents more than 40 percent of our health premiums.”


    “With all the politics of the Affordable Care Act, people don’t realize how much the industry has benefited, and will continue to benefit, from the law,” said Jay Angoff, the Obama administration’s top insurance regulator from 2010 through 2012.

    One insurer, Humana, derives about 65 percent of its revenue from its Medicare Advantage plans. Enrollment in these plans climbed 17.5 percent, to 2.9 million, in the year that ended Sept. 30, the company said.

    At UnitedHealth Group, Medicaid and Medicare Advantage together are expected to provide more than $60 billion in revenue, or slightly less than half of the company’s total, this year. United expects to participate in insurance exchanges in 23 states next year, up from four this year.

    “The government, as a benefit sponsor, has been increasingly relying on private sector programs,” United said in a document filed with the Securities and Exchange Commission. “We expect this trend to continue.”

    In another sign of the close relationship, the administration has recruited experts from the industry to provide operational expertise.

  • #2
    Re: Who wrote the 2,000 page Affordable Care Act?

    “With all the politics of the Affordable Care Act, people don’t realize how much the industry has benefited, and will continue to benefit, from the law,” said Jay Angoff, the Obama administration’s top insurance regulator from 2010 through 2012.
    Speak for yourself buddy. Loads of people raised red flags before this bill was passed. The demagogues insisted it was a "step in the right direction" or "the system is broken we must change it".

    This is typical politics. The politicians identify a "problem" and then strive not to fix it while claiming that they are "doing something". The ignorant public laps it up. It only takes a few happy folks to swing an election and there are plenty of folks who are easily impressed with useless actions.

    We are becoming a corrupt society. Nothing will change until our hearts change. Legislation only works when there are honest people enforcing the laws and mostly honest people following the laws.

    This whole ACA thing was a blatant play on greed. The "people" thought they were getting something for nothing, then act surprised when it turns out to be a fake.

    Comment


    • #3
      Re: Who wrote the 2,000 page Affordable Care Act?

      Originally posted by LorenS View Post
      Speak for yourself buddy. ....
      ....
      ...
      This whole ACA thing was a blatant play on greed. The "people" thought they were getting something for nothing, then act surprised when it turns out to be a fake.
      +1

      Comment


      • #4
        Re: Who wrote the 2,000 page Affordable Care Act?

        Jonathan Gruber warned Wisconsin governor of premium spikes in 2010 while Obama promised savings:

        http://www.washingtontimes.com/news/...remium-spike-/

        https://www.youtube.com/watch?v=2o0V6VPX_E0

        Comment


        • #5
          Re: Who wrote the 2,000 page Affordable Care Act?

          I work for a fortune 500 company, and just completed my Annual enrollment for 2015.

          We went from a transitional plan last year to a bronze, silver, gold plan this year. The HR people tried to spin the notion that last year's plan was a silver plan, but by doing the math this statement was shown to be not correct. The silver plan had a lower employer HRA contribution (1000 to 500) much higher deductibles (1500- 4000) and higher max out of pocket (10,000-12,000). Because of the high deductible, and higher out of pocket, I was forced into a gold plan and my annual premiums are 30% higher than last year. Because of the gold's lower deductible i think my total out of pocket will be lower than with the silver, and for just a few dollars more out of pocket, I have the increased insurance if a big medical bill hits. Additionally
          medical premiums are tax deductible, and oop medical expenses are only deductible once they exceed 7.5%?? of your AGI. The ACA has also seen fit to lower flexible spending account maximums?????. This 30% increase on premiums was on the back of a 20% increase in premiums from 2013 to 2014.

          These increases in the 1,000 dollar per year range are going to grind the middle class into the dust. How many extra 1000s a year in discretionary income to the politicians think I or any other working Joe or Jane have?

          I hope someone sues the federal gvt on this. We were promised if we like our policy we can keep our policy, if we like our doctor we can keep our doctor and our premiums would decrease. All not true. Who would do that?? a cadre of state A.G.'s???

          Comment


          • #6
            Re: Who wrote the 2,000 page Affordable Care Act?

            Don't forget to tune in to the Gruber Show in front of Congress Tuesday morning:

            http://www.politico.com/magazine/sto...l#.VIUg4jGjOM4

            Comment


            • #7
              Specific Problems with OC

              Originally posted by don View Post
              ​who do you think . . .

              “Insurers and the government have developed a symbiotic relationship, nurtured by tens of billions of dollars that flow from the federal Treasury to insurers each year.” Michael F. Cannon, director of health policy studies at the libertarian Cato Institute.

              .

              Problems with Obama Care:

              a) The sheer complexity of the system is daunting.

              b) if your income is low enough to qualify for medicaid, but you refuse medicaid, you get no help in the marketplace.

              You might want to refuse medicaid just because some doctors/clinics won't take it. Then you get no help At All.

              Great system they came up with!

              With all this, I blame the Republicans.

              Why did they not come up with some free market based ideas, and offer a plan to compete with AHA?

              Instead, they just moaned and groaned, and AHA became law.

              Here's what they could have done:

              1) eliminate the tax deduction for healthcare,

              2) Require all non-profit hospitals (at least) to disclose all expenses, salaries and service charges

              3) Offer some basic services to all US citizens (start with just an annual physical)

              4) Prevent "restraint of trade" clauses in agreements between insurers and medical service providers.
              (they have lots of these)

              Comment


              • #8
                Re: Specific Problems with OC

                ​My wife has wet macular degeneration in one eye. Her treatment originally was Lucentis which proved less effective. She's now receiving Avastin, which in her case was a better choice.

                Paid to Promote Eye Drug, and Prescribing It Widely

                By KATIE THOMAS and RACHEL ABRAMSWhen the drug maker Genentech introduced a major product in 2006, it found itself in an awkward position: persuading eye doctors to start using its new more expensive drug instead of a popular cheaper version that the company already sold.

                Ophthalmologists had been enthusiastically using the company’s cancer drug Avastin, which cost about $50 a dose, to treat a common eye disease in the elderly, wet macular degeneration. Then Genentech introduced Lucentis, a nearly equivalent drug that cost $2,000 a dose and was approved specifically to treat the disease.

                Use of Lucentis took off, and it has become one of Medicare’s most expensive treatments — costing the federal government about $1 billion a year — even though several studies have concluded Lucentis has no significant advantage over its cheaper alternative.

                Now, a new federal database shows that many of the doctors who were the top billers for Lucentis were also among the highest-paid consultants for Genentech, earning thousands of dollars to help promote the drug. The data raises questions about whether financial relationships between doctors and drug companies influence treatment decisions, even though physicians maintain they cannot be swayed.

                Half of the 20 doctors who received the most money from Genentech to promote Lucentis in 2013 were among the highest users of the drug in 2012, billing for higher amounts of Lucentis than 75 percent of their peers. The figures were compiled from two federal databases that covered different periods, and it is not known whether or how much Genentech paid the doctors in 2012.

                The 20 doctors earned $8,500 to $37,000 over five months in 2013, payments that included consulting and speaking fees as well as travel expenses and meals. Genentech says it has an annual cap of $50,000 a doctor for speaking fees.

                Specialists who study conflicts of interest between physicians and the drug industry say even modest payments have been shown to influence behavior.

                “That’s why a sandwich is so effective — no one wants to feel like they were being bought off for $5,” said Dr. Adriane Fugh-Berman, an associate professor at Georgetown University Medical Center in Washington and director of PharmedOut, a project that educates doctors about drug marketing claims. “That’s why they convince themselves that the drug is better.”

                Doctors who speak on behalf of Lucentis say they do so because they believe in it and because they want to educate colleagues on its use. Some said that while they continued to use Avastin, it carried risks that should not be ignored.

                “There are certain instances where you would prefer one over the other,” said Alan Ruby, an ophthalmologist based in Livonia, Mich., who received nearly $12,000 from Genentech in the second half of 2013 for conducting what he described as workshops to educate other medical professionals about Lucentis. Dr. Ruby said that Lucentis was a better choice for some patients because of some evidence showing that Avastin carries a slightly higher chance of strokes in patients who are already at risk of developing them.

                Dr. Ruby said he used Avastin on roughly a quarter of his macular degeneration patients, and used Lucentis more frequently. A federal database of Medicare billing showed that he billed for a higher amount of Lucentis than 75 percent of his peers. “I think to suggest that physicians are in any way influenced by their interactions with drug companies is very shortsighted,” he said.

                Edward Lang Jr., a spokesman for Genentech, which is owned by the Swiss drug maker Roche, said the company chose to work with doctors based on their clinical expertise. “We’re looking to work with doctors who are in the top of their field, and who can provide us an honest perspective on what patients need and don’t need,” he said.

                While Genentech says Lucentis is a better option, it supports a doctor’s choice about what is best for a patient, Mr. Lang said, adding, “That comes before us and anything else.”

                Lucentis and Avastin, as well as Regeneron’s drug Eylea, are prescribed for the eye disease, which, if left untreated, can lead to blindness. Use of Avastin became popular after clinical trials for Lucentis showed that it worked well for macular degeneration. Doctors speculated that Avastin, which works in the same way as Lucentis, could also be used to treat the disease.

                Since Lucentis was approved in 2006, several studies have shown that the drugs are nearly equivalent, including a large government-sponsored clinical trial involving 1,200 patients that was completed in 2011. Avastin is still the most popular choice of doctors: About half of patients who were treated for wet macular degeneration received Avastin, with Lucentis and Eylea sharing the rest of the market.

                Genentech has aggressively promoted Lucentis to doctors to encourage them to switch, even paying rebates to those who use large amounts of Lucentis, a practice that critics have described as improper but the company says is legal. For Genentech, the stakes are high. Lucentis is one of its top products, generating $1.3 billion in sales in the first nine months of this year, an increase of 5 percent over that period last year.

                Even with widespread Avastin use, injecting Lucentis remains one of Medicare’s costliest procedures. In 2010, Medicare paid $1 billion to treat macular degeneration patients with Lucentis, while it spent $27 million for such patients treated with Avastin, according to a 2012 study from the Office of the Inspector General for the Department of Health and Human Services.

                In 2011, the office determined that if all patients being treated with Lucentis were instead given Avastin, the federal government would have saved about $1.4 billion.

                A review released this year of nine clinical trials showed that Avastin and Lucentis had similar safety profiles and that Avastin did not appear to increase deaths or serious side effects. The review was conducted by the nonprofit Cochrane Collaboration.

                Still, several doctors, including those who speak on behalf of Lucentis and those who do not, said the choice between Avastin and Lucentis was not simply a matter of cost.

                For example, Lucentis is specially prepared to be injected into the eye, but Avastin must be divided into smaller doses by outside compounding pharmacies, which can lead to contamination in rare cases. In 2011, more than a dozen people developed severe eye infections, and some were blinded, after they received injections of contaminated Avastin.

                Some doctors say there is no good reason to use Lucentis more frequently than Avastin.

                “They keep talking about evidence-based medicine, and they keep pretending the corporate-sponsored research is nonbiased,” said J. Gregory Rosenthal, a retina specialist in Toledo who has become an outspoken critic of Lucentis and Eylea. “The evidence says that Avastin has at least the clinical efficacy of Lucentis and is perhaps safer.”

                Some doctors who were paid to promote Lucentis said they also used Avastin. “I usually start with Avastin,” said Dr. Mathew MacCumber, a retina specialist in Illinois who received about $8,500 from Genentech from August through December 2013, mostly to advise the company on topics that included how to promote the drug to doctors.

                He received even more, about $16,000, from Regeneron in connection with Eylea, which was approved in 2011. Dr. MacCumber says he switches patients to Lucentis or Eylea if they do not do well on Avastin. He said some patients asked for those two drugs because they are F.D.A.-approved to treat macular degeneration. The federal Medicare database showed that the amount he billed for Lucentis was more than 50 percent of his peers. Dr. MacCumber, who noted he is a retina specialist who treats a high number of patients with macular degeneration, said he also used Lucentis to treat other eye conditions.

                Dr. MacCumber said he worked for the companies because it was the best way to learn about the drugs. He says he is not influenced by the money he receives in compensation for his time. “People come to me and ask my advice, so I have to know the real story about things, and the only way to really do that is to know the people in the company who do the research, who know the drug the best,” he said.

                Eric Campbell, a professor of health care policy at Harvard Medical School, said doctors frequently denied that relationships with drug companies could change their behavior, despite many studies to the contrary. “They are suggesting that the drug companies that are spending this money, that these companies are dumb enough to be wasting their money,” he said.

                Not every top Lucentis biller was paid to promote the drug. In fact, several of the highest billers in 2012 got no such payments.

                Mr. Campbell said that was because drug companies selected doctors based on their sway in their community. “You don’t have to influence every doctor, you just have to influence the right doctors,” he said.

                Comment


                • #9
                  Re: Specific Problems with OC

                  Originally posted by Polish_Silver View Post
                  Problems with Obama Care:

                  a) The sheer complexity of the system is daunting.

                  b) if your income is low enough to qualify for medicaid, but you refuse medicaid, you get no help in the marketplace.

                  You might want to refuse medicaid just because some doctors/clinics won't take it. Then you get no help At All.

                  Great system they came up with!

                  With all this, I blame the Republicans.

                  Why did they not come up with some free market based ideas, and offer a plan to compete with AHA?

                  Instead, they just moaned and groaned, and AHA became law.

                  Here's what they could have done:

                  1) eliminate the tax deduction for healthcare,

                  2) Require all non-profit hospitals (at least) to disclose all expenses, salaries and service charges

                  3) Offer some basic services to all US citizens (start with just an annual physical)

                  4) Prevent "restraint of trade" clauses in agreements between insurers and medical service providers.
                  (they have lots of these)
                  Can't disagree with what you laid out, Silver, though I lean towards:

                  the pilot program for Obamacare was Romneycare

                  the Repubs are financed by the "Healthcare Industry" as well as the Dems

                  in cases of windfall legislation (this one is a whopper, hence the 2,000+ pages), roles are assigned to each "party", while distracting the sheeple, never threaten the agenda of their paymasters

                  Comment


                  • #10
                    Re: Specific Problems with OC

                    Originally posted by don View Post
                    . . .

                    in cases of windfall legislation (this one is a whopper, hence the 2,000+ pages), roles are assigned to each "party", while distracting the sheeple, never threaten the agenda of their paymasters
                    That would explain why the republicans never came up with a separate plan.

                    There was a guy on Diane Rheme talking about exactly that, "double milker" but I'm not sure I could find the link. He claims most of the political gridlock and infighting is just show---like professional wrestling.

                    Comment


                    • #11
                      Re: Specific Problems with OC

                      Originally posted by Polish_Silver View Post
                      That would explain why the republicans never came up with a separate plan.

                      There was a guy on Diane Rheme talking about exactly that, "double milker" but I'm not sure I could find the link. He claims most of the political gridlock and infighting is just show---like professional wrestling.
                      Just follow the money.

                      Comment


                      • #12
                        Re: Specific Problems with OC

                        The Republicans did have plans; they just couldn't get any support from the democrats who were unwilling to compromise:

                        http://www.forbes.com/sites/theapoth...o-health-plan/

                        Comment


                        • #13
                          Re: Specific Problems with OC

                          Vermont gives up on single payer:

                          http://dailycaller.com/2014/12/17/ve...looning-costs/

                          Comment


                          • #14
                            Re: Specific Problems with OC

                            The Great Generic Drug Rip-Off

                            Posted on December 16, 2014 by Charles Hugh Smith

                            Big Pharma has followed the only avenue left to reap billion-dollar profits: jack up the price of generics.

                            What happens when rapacious cartels run out of billion-dollar-profit products? They jack up the price of what was previously low-cost. And why are they able to raise prices by 388% to 8,000% at will? Because they can. That’s the whole point in having a cartel that is enabled and enforced by the cartel’s toadies and apologists in the central state (federal government): price increases can be imposed on the government and the private sector at will.

                            I was alerted to the extraordinary price increases in widely used generic drugs by Ishabaka (M.D.), who forwarded this fact sheet issued by the office of Senator Bernie Sanders: (Chart is reproduced below)

                            Staggering Price Increases for Generic Drugs

                            “Rep. Elijah E. Cummings and Senator Bernard Sanders sent letters to 14 drug manufacturers requesting information about the escalating prices of generic drugs used to treat everything from common medical conditions to life-threatening illnesses. Data was provided by the Healthcare Supply Chain Association (HSCA) on recent purchases by group purchasing organizations (GPOs) of ten generic drugs.”

                            Here are Ishabaka’s comments:

                            “I’d like to focus on the top one – doxycycline. This is a very effective antibiotic for pneumonia, bronchitis, and sexually transmitted diseases (chlamydia and gonorrhea). Throughout my medical career, it has been a cheap generic drug I used all the time. It’s cost has gone up from $20 a prescription to over $1,600 a prescription in the last 12 months.

                            Low-income people used to be able to afford doxycycline, which would stop the spread of these serious, sometimes life-threatening infections. Now they can’t, and there is no drug as good as doxycycline available cheaply. I think this is an outrage. Imagine if a generic bottle of aspirin increased in price from $10 a bottle to $800 a bottle in 12 months.”

                            Drug Use Average Market Price Oct. 2013 Average Market Price April 2014 Average Percentage Increase
                            Doxycycline Hyclate
                            (bottle of 500, 100 mg tablets)
                            antibiotic used to treat a variety of infections $20 $1,849 8,281%
                            Albuterol Sulfate
                            (bottle of 100, 2 mg tablets)
                            used to treat asthma and other lung conditions $11 $434 4,014%
                            Glycopyrrolate
                            (box of 10 0.2 mg/mL, 20 mL vials)
                            used to prevent irregular heartbeats during surgery $65 $1,277 2,728%
                            Divalproex Sodium ER
                            (bottle of 80, 500 mg tablets ER 24H)
                            used to prevent migraines and treat certain types of seizures $31 $234 736%
                            Pravastatin Sodium
                            (bottle of 500, 10 mg tablets)
                            used to treat high cholesterol and to prevent heart disease $27 $196 573%
                            Neostigmine Methylsulfate
                            (box of 10 1:1000 vials)
                            used in anesthesia to reverse the effects of some muscle relaxants $25 $121 522%
                            Benazepril/
                            Hydrochlorothiazide
                            (bottle of 100, 20-25 mg tablets)
                            used to treat high blood pressure $34 $149 420%
                            Isuprel
                            (box of 25, 0.2 mg/mL vials)
                            used to treat heart attacks and irregular heartbeat $916 $4,489 390%
                            Nitropress
                            (50 mg vial)
                            used to treat congestive heart failure and reduce blood pressure $44 $215 388%
                            Digoxin
                            (single tablet, 250 mcg)
                            used to treat irregular heartbeats and heart failure $0.11 $1.10

                            Comment


                            • #15
                              Re: Specific Problems with OC

                              This is criminal and needs to be addressed immediately in the new Congress.

                              Comment

                              Working...
                              X